Dysport vs Botox vs Xeomin vs Jeuveau vs Daxxify: Neurotoxins Compared

Five botulinum toxin type A products now compete for the same job: relaxing the muscles that cause frown lines, crow's feet, and forehead wrinkles. They share a mechanism and a strong safety record, but they differ in dose units, onset speed, how far they spread, how long they last, and how much they cost. This guide walks through what the evidence actually shows about Botox, Dysport, Xeomin, Jeuveau, and Daxxify, where the head-to-head data is solid, and where marketing has gotten ahead of the science.

What These Products Actually Are

All five are formulations of botulinum toxin type A, a protein made by the bacterium Clostridium botulinum. When injected in tiny, purified amounts into a muscle, the toxin blocks the nerve signal that tells the muscle to contract. The muscle relaxes, the overlying skin stops creasing, and dynamic wrinkles soften. The effect is temporary because nerve endings regrow over the following months.

The active ingredient is the same family of molecule in every product. What changes is the manufacturer, the formulation around the toxin, and the FDA-assigned generic name. Those generic names matter because units are not interchangeable between brands. A unit of one product does not equal a unit of another.

To be precise about the mechanism: when a nerve normally fires, it releases a chemical messenger called acetylcholine that crosses the gap to the muscle and tells it to contract. Botulinum toxin type A cleaves a protein called SNAP-25 inside the nerve ending. Without intact SNAP-25, the nerve can't dump acetylcholine into that gap. The signal never arrives, so the muscle stays quiet. Because the toxin only silences the nerve ending it reaches, and because nerve endings sprout new connections over the following months, the effect is local and reversible. That regrowth timeline is roughly why most products wear off in a season.

All five carry the same single FDA-approved cosmetic indication for the U.S. consumer: temporary improvement of moderate to severe glabellar lines (the "11" frown lines between the brows). Botox and Dysport also have FDA cosmetic clearance for crow's feet and forehead lines. Everything else you hear about, such as masseter slimming, neck bands, or a "lip flip," is off-label. Off-label is legal and common, but it means the FDA has not formally reviewed that specific cosmetic use.

How They Differ Under the Hood

The five products are not five copies of one drug. Three differences drive most of the real-world variation.

Complexing proteins. Botox, Dysport, Jeuveau, and Daxxify package the active 150-kilodalton neurotoxin inside a cluster of accessory proteins. Xeomin strips these away and delivers the bare toxin. The theory is that fewer foreign proteins means a lower chance your immune system builds antibodies that neutralize the drug over years of repeat treatment. The theory is biologically reasonable. The clinical proof that this matters for the average cosmetic patient is thin, because antibody-driven resistance is rare with modern, low-dose products, and long head-to-head trials in treatment-naive people are lacking.

Molecule size and spread. Dysport's complex is smaller and tends to diffuse a bit wider from the injection point. Injectors use that on purpose for broad, flat areas like the forehead, where a softer, blended look is wanted. The same spread is a liability near the eye, where toxin drifting into the wrong muscle can cause a droopy lid. Botox and Xeomin are generally treated as more contained.

Stabilizer chemistry. Daxxify swaps the usual human serum albumin for a proprietary peptide. Revance argues this peptide helps the toxin bind longer, which is the basis for its longer-duration marketing. The chemistry is novel. Whether it reliably buys you extra months in everyday practice is still being sorted out.

Onset: How Fast You See Results

Most people see some softening within 2 to 4 days and the full effect by 10 to 14 days, regardless of brand. But there are measurable differences at the early checkpoint.

In a 2025 single-center, double-blind randomized trial at the University of Pennsylvania, 143 women were assigned to one of the four older toxins at standard doses (onabotulinumtoxinA 20 units, abobotulinumtoxinA 60 units, prabotulinumtoxinA 20 units, incobotulinumtoxinA 20 units) and followed at days 3, 30, 90, and 180. Dysport (abo) and Jeuveau (prabo) had the fastest onset at day 3 (Lemdani et al., JAMA Dermatology, 2025). If seeing a result before a weekend event matters, those two have a slight edge in this dataset. One caveat worth stating plainly: that trial received grants from Evolus, the maker of Jeuveau, so independent replication would strengthen the finding.

Daxxify markets a fast onset too, with the company reporting results in about 2 days for some patients in its SAKURA program. That sits in the same general range as the rest.

Duration: The Most Marketed and Most Confused Claim

Duration is where the hype is loudest, so read this section carefully.

For Botox, Dysport, Xeomin, and Jeuveau, the honest answer is that they last about the same: roughly 3 to 4 months for most people in the glabella. Network meta-analysis pooling many randomized trials found the four established toxins broadly comparable in efficacy and safety for frown lines, without one clearly dominating (Li et al., Aesthetic Plastic Surgery, 2023). Individual biology, dose, and the muscle treated swing duration more than the brand does.

The 2025 head-to-head trial did find a longevity signal: at day 180, Jeuveau (prabo) and Xeomin (inco) still showed measurable benefit versus their own baseline, and Jeuveau was significantly more effective than Botox at that six-month mark (Lemdani et al., 2025). That is interesting and suggests the duration story is more nuanced than "all the same." But it is a single, industry-funded study, the differences at six months were modest, and most patients still return for retreatment around the 3-to-4-month window. Treat it as a hint, not a settled fact.

Daxxify is the genuine outlier on duration, with caveats. Revance's SAKURA phase 3 program reported a median duration of about 6 months, with some patients holding results up to 9 months. That is the longest claim in the category, and the FDA reviewed the data behind it (FDA Drug Trials Snapshot: DAXXIFY). Two honest qualifiers: "median 6 months" means half of patients fell below that, and the headline duration is defined by when frown lines return to baseline, not when they look their best, which is a softer threshold. In a phase 2 study, 40 units of daxibotulinumtoxinA did beat 20 units of onabotulinumtoxinA on duration (median 24 weeks vs 19 weeks) (Carruthers et al., Dermatologic Surgery, 2017). So the longer-duration claim has support. Just don't assume you personally will get nine months.

The Units Problem Nobody Explains at the Counter

This is the single most useful thing to understand before you compare prices.

Dysport units are smaller than Botox units. The widely used conversion is roughly 2.5 to 3 Dysport units to 1 Botox unit, a ratio supported by movement-disorder and aesthetic dosing research, though the exact figure has ranged in the literature. So if a clinic advertises "Dysport $4 a unit" and "Botox $12 a unit," that is not a 3x savings. Once you convert, the per-treatment cost is often similar. A typical frown-line treatment might use ~20 Botox units or ~50–60 Dysport units to achieve a comparable result.

Xeomin and Jeuveau are generally dosed close to 1:1 with Botox, which makes their per-unit prices more directly comparable. Daxxify uses its own unit scale; do not map it onto Botox units. Always ask a clinic to quote the total cost per treatment area, not just the price per unit. Per-unit pricing without the conversion is the most common way the real cost gets obscured.

A worked example makes this concrete. Say a clinic lists Botox at $13 per unit and Dysport at $5 per unit. The frown lines need about 20 Botox units, which is $260. The same correction in Dysport needs roughly 50 to 60 units at the 2.5–3:1 conversion, which is $250 to $300. The headline per-unit numbers looked like a huge gap. The actual treatment costs land within a few dollars of each other. Jeuveau, dosed near 1:1 with Botox and often priced lower per unit, is where a real per-treatment discount tends to show up. Daxxify usually costs the most per session, but if its longer duration holds for you, the cost per month of effect can come out closer to the others. Run the math on cost per month, not cost per visit, when duration is part of the decision.

Cost ballpark by area

Prices vary widely by city and injector, but rough U.S. ranges in 2026 look like this for a single treatment of one area: frown lines ($200–$400), forehead lines ($150–$350), and crow's feet ($200–$400). A full upper-face treatment combining all three commonly lands between $500 and $1,000. Daxxify sessions often run 20 to 40 percent higher than the others for the same area. None of these are covered by insurance when done for cosmetic reasons, because cosmetic wrinkle treatment is elective.

Efficacy: What the Trials Show, Honestly

Every one of these products beats placebo decisively for glabellar lines. That is not in question.

• Botox has the deepest and longest record. Two decades of trials and real-world use make it the reference standard.
• Jeuveau was shown non-inferior to Botox in the largest head-to-head phase 3 glabellar trial, with day-30 responder rates around 87 percent for Jeuveau versus about 83 percent for Botox (Rzany et al., Aesthetic Surgery Journal, 2020). For the frown lines it is approved to treat, it works like Botox.
• Xeomin met a stringent composite efficacy endpoint versus placebo in phase 3 and is broadly comparable to Botox at roughly 1:1 dosing (Hanke et al., Dermatologic Surgery, 2013).
• Dysport matches Botox on efficacy when dosed at the correct conversion ratio; mismatches in older studies usually trace back to under- or over-dosing.
• Daxxify delivered high response rates in SAKURA (a large majority of patients reaching a 2-grade improvement at week 4) and its differentiator is duration, not a higher peak effect (FDA Drug Trials Snapshot).

Where the evidence gets weak or mixed: cross-brand duration claims, the practical importance of Xeomin's antibody advantage in average patients, and most off-label uses (masseter, neck bands, lip flip), which rest more on clinical experience than on large randomized trials. Be skeptical of any clinic claiming one brand is dramatically "better" for standard frown lines. The data don't support a wide gap among the four established toxins.

It's also worth naming a structural problem in this field: a large share of the head-to-head studies are funded by the company that stands to benefit. The 2025 trial favoring Jeuveau's six-month performance was grant-funded by Evolus. Daxxify's duration data come from Revance's own SAKURA program. That doesn't make the results fake; the FDA reviewed the pivotal data, and the trials were generally well designed. But it should temper how much weight you put on any single "our toxin wins" claim. The most trustworthy reads come from independent network meta-analyses that pool many trials, and those tend to find the established four roughly even.

Treatment Areas and How Brand Choice Shifts

The right product can depend on where it's going.

Frown lines (glabella). The one area all five are FDA-approved for. Any of them works well. Contained spread is slightly preferred here because the muscles sit close to the eyelid-lifting muscles, and unwanted drift can cause brow or lid droop. Botox, Xeomin, and Jeuveau are the conventional picks.

Forehead lines. Off-label for all brands as a standalone area, though extremely common. Dysport's wider spread can be an asset across the broad, flat forehead, giving a smoother blend with fewer injection points. Over-treating the forehead is the classic cause of a heavy, frozen brow, so conservative dosing matters more than brand.

Crow's feet. Botox and Dysport carry FDA cosmetic approval here. The skin is thin and the area is delicate, so many injectors favor a contained product and a light hand.

Lower face and off-label uses. Masseter slimming for a softer jawline, "lip flip" for a fuller-looking upper lip, neck bands, and a "Nefertiti lift" are all done with these toxins but are off-label. The evidence is mostly clinical experience and smaller studies rather than large randomized trials. They can work well in skilled hands, but you're further from the firm data here, and dosing is more art than protocol.

Safety: Shared Risks and the Boxed Warning

The safety profile is similar across all five because the mechanism is identical. Common, mild, and temporary side effects include injection-site bruising, redness, headache, and, less often, a heavy brow or a droopy eyelid (ptosis) if toxin migrates to the wrong muscle. Eyelid droop typically resolves over weeks as the effect fades.

All botulinum toxin products carry an FDA boxed warning, the agency's strongest, about the theoretical risk of the toxin spreading beyond the injection site and causing botulism-like symptoms such as trouble swallowing, breathing, or generalized muscle weakness (Xeomin FDA prescribing information). For cosmetic doses in the face, distant spread is very rare, and serious events at aesthetic doses are uncommon. The warning exists largely because high therapeutic doses in conditions like spasticity carry more risk. Still, it is real, and it is why these drugs should only be injected by trained, licensed clinicians.

On the immunogenicity question, Daxxify's SAKURA data are reassuring: across roughly 2,800 treated patients, binding antibodies appeared in fewer than 1 percent and no patient developed neutralizing antibodies (Gallagher et al., Toxins, 2023). Modern products across the board show low rates of clinically meaningful resistance. Xeomin's protein-free design is the most plausible long-term hedge if you treat frequently for years, but again, the everyday advantage is unproven.

Who should avoid these entirely: people with known allergy to any component, an active skin infection at the injection site, or certain neuromuscular disorders such as myasthenia gravis or ALS. Pregnancy and breastfeeding are standard reasons to wait, since safety data are lacking.

Who Each One Is For

There is no universal winner. Match the product to your goal and your treatment area.

• Choose Botox if you want the most studied option, predictable and contained results, and a track record for delicate areas like crow's feet. Good default for first-timers.
• Choose Dysport if you're treating a broad zone like the forehead and want fast onset with a softer, blended spread. Often quoted cheaply per unit, so insist on the converted total.
• Choose Xeomin if you treat frequently and want the lowest theoretical risk of building resistance over years, or if you prefer a minimalist formulation.
• Choose Jeuveau if cost matters and you want a cosmetics-focused toxin with fast onset and Botox-equivalent results for frown lines. Often the value play.
• Choose Daxxify if longer time between appointments is your priority and you're comfortable paying more, accepting that "median 6 months" is an average, not a guarantee.

For most people, the injector matters more than the brand. Placement, dose, and anatomy knowledge drive results far more than which of these five vials gets opened. A skilled injector with Botox will beat a careless one with the priciest toxin every time.

If you're weighing neurotoxins against other approaches, it helps to see how they fit the broader menu. Compare them with collagen-stimulating and volumizing options in Botox vs dermal fillers and the full injectables guide to Botox, fillers, and what they cost. For lines driven by skin texture rather than muscle movement, Botox vs microneedling lays out when a resurfacing approach makes more sense. And before booking anywhere, run through the spa and med spa safety checklist to vet the clinic and injector.

Frequently Asked Questions

Is one neurotoxin clearly better than the others?

No. For standard frown lines, Botox, Dysport, Xeomin, and Jeuveau perform comparably in pooled randomized trials when dosed correctly. Daxxify's main distinction is longer median duration, not a stronger or better-looking result. The biggest variable in your outcome is the skill of the injector, not the brand on the vial.

Why does Dysport seem so much cheaper per unit?

Because Dysport units are smaller than Botox units. The rough conversion is about 2.5 to 3 Dysport units per 1 Botox unit, so a treatment that uses 20 Botox units might use 50 to 60 Dysport units. After converting, the total cost per treatment is usually similar. Always ask for the price per treatment area, not per unit.

How long until I see results, and how long do they last?

Most people see softening in 2 to 4 days and the full effect by 10 to 14 days across all brands. Dysport and Jeuveau showed the fastest onset at day 3 in a 2025 head-to-head trial. Botox, Dysport, Xeomin, and Jeuveau typically last 3 to 4 months in the frown lines; Daxxify reports a median of about 6 months.

Can I switch brands between appointments?

Yes. Switching is common and generally safe because all five work the same way. Your injector will recalculate the dose, since units don't transfer one-to-one. Some people switch hoping to extend results or reduce resistance, but there's no strong evidence that rotating brands meaningfully changes outcomes for the average patient.

Are these injections safe, and what are the real risks?

At cosmetic facial doses, serious problems are rare, and these products have a long safety record. Common side effects are mild and temporary: bruising, headache, and occasionally a droopy brow or eyelid that resolves as the effect fades. All carry an FDA boxed warning about the theoretical spread of toxin beyond the injection site, which is why only trained, licensed clinicians should inject them.

This article is for general education only and is not medical advice. Botulinum toxin treatments carry risks and should be discussed with a licensed medical provider who can evaluate your individual situation.